Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

NCT03158805 on ClinicalTrials.gov · last registry update 2025-03-12

Finished 11 October 2022, after enrolling 60 people. Primary outcome, as filed: Percent Change in Body Weight. liraglutide is approved in the US, but not for psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Lindner Center of HOPE
Sponsor type: Other
Enrollment: 60
Started: 2017-04-26
Primary completion: 2022-10-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change in Body Weight

Conditions studied

Bipolar Disorder · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.